In the first half of 2023, Eli Lilly successfully ascended to the top of global pharmaceutical market value, especially with a short-term stock price increase of nearly 50% under such a large volume.

Longeveron Inc. announced promising preliminary results from their Phase 2a trial with Lomecel-B™, aimed at treating mild Alzheimer’s disease.

This article summarized the latest R&D progress of gemcitabine hydrochloride, the Mechanism of Action for gemcitabine hydrochloride, and the drug target R&D trends for gemcitabine hydrochloride.

Freeline Therapeutics reported positive preliminary results on safety, tolerability, and enzyme action from their ongoing Phase 1/2 GALILEO-1 study evaluating FLT201, their gene therapy candidate for Gaucher disease.

More than one encoding rule for CDR sequences is required to reduce the risk of missing FTO sequences in antibody searches.

This article summarized the latest R&D progress of granisetron hydrochloride, the Mechanism of Action for granisetron hydrochloride, and the drug target R&D trends for granisetron hydrochloride.

Disease-Specific Survival (DSS) refers to deaths caused specifically by a particular disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Milestone survival rate is defined as the survival probability at a given point in time.

This article summarized the latest R&D progress of imiglucerase, the Mechanism of Action for imiglucerase, and the drug target R&D trends for imiglucerase.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.

This article summarized the latest R&D progress of infliximab-abda, the Mechanism of Action for infliximab-abda, and the drug target R&D trends for infliximab-abda.